Tag: warfarin

Blood Thinners and the Genetics Behind Drug Response

A study in the journal Lancet regarding a new blood thinning drug brings to mind the difficulty doctors and patients have in using anticoagulants to prevent clots that could otherwise lead to heart attacks or strokes. The mostly commonly used blood thinner, warfarin (Coumadin®) has proven to be a godsend ...

Read more

23andMe Launches Its First NIH Funded Study

  By Amy Kiefer and Kim Barnholt 23andMe is excited to announce the launch of our first National Institutes of Health (NIH) funded research project. In the fall of 2010, 23andMe received a NIH Small Business Innovative Research Grant (SBIR) to validate our web-based approach to pharmacogenomics ...

Read more

Genetic Tests Can Reduce Risks From Blood Thinner Warfarin

Editor’s note: Pending an FDA decision, 23andMe no longer offers new customers access to health reports referred to in this post. Customers who purchased prior to November 22, 2013 will still be able to see their health reports, but those who purchased after that time will not. Those customers will have ...

Read more

FDA Updates Label for Commonly Used Blood Thinner to Include Dosing Recommendations Based on Genetics

Warfarin (Coumadin®) is a blood thinner given to people at high risk for the formation of blood clots due to conditions such as deep vein thrombosis, heart valve disease or replacement, and irregular heart beat. The drug is also given to prevent recurrence of pulmonary embolism, heart attack and stroke. If ...

Read more

New Study Shows That Genetic Information Can Improve Administration Of Commonly Used Blood Thinner

Each time a doctor writes a prescription for warfarin (Coumadin®), a blood thinner given to about two million people each year in the United States, it’s a guessing game.  There is no “right” dose of the drug.  Everyone is different and it can take weeks of adjustment to find a patient’s ideal amount of the ...

Read more

Return to top